<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="139512">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01860482</url>
  </required_header>
  <id_info>
    <org_study_id>243GERD13003</org_study_id>
    <nct_id>NCT01860482</nct_id>
  </id_info>
  <brief_title>The Study to Evaluate Efficacy and Safety of Newrabell® Tab.(Rabeprazole Sodium) 10mg b.i.d in Refractory GERD</brief_title>
  <official_title>An 8-weeks, Multicenter, Single Arm, Non-comparative, Phase 4 Clinical Trial to Assess the Efficacy and Safety of Newrabell® Tab. at 10mg b.i.d in Patients With Refractory Reflux Esophagitis(rGERD) to the Prior Standard PPIs Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of Newrabell® Tab. in
      patients with refractory reflux esophagitis to the prior standard PPIs regimen.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time to onset of first 1Day Heartburn free, Days</measure>
    <time_frame>up to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to onset of first 2Days Heartburn free, Days</measure>
    <time_frame>up to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1Day Heartburn free days, %</measure>
    <time_frame>up to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in Daytime of first Heartburn free, Days</measure>
    <time_frame>up to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in Nighttime of first Heartburn free, Days</measure>
    <time_frame>up to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly Heartburn Improvement Rate, %</measure>
    <time_frame>up to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Daytime and Nighttime Heartburn Score Change at W4</measure>
    <time_frame>up to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Daytime and Nighttime Heartburn Score Change at W8</measure>
    <time_frame>up to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Reflux Esophagitis</condition>
  <arm_group>
    <arm_group_label>Newrabell single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Newrabell® Tablet 10mg b.i.d PO during 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Newrabell® Tablet 10mg</intervention_name>
    <arm_group_label>Newrabell single arm</arm_group_label>
    <other_name>Rabeprazole sodium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or Female aged ≥ 20 years

          2. Reflux esophagitis with erosion or ulceration confirmed by endoscopic exam.

          3. Refractory reflux esophagitis to PPIs standard treatment as follows

               1. Ongoing heartburn symptom with or without these GERD-related symptoms :
                  Regurgitation, Non-cardiac chest pain, Epigastric pain, Belching, Bloating,
                  Satiety, Sore throat, Cough, Laryngitis, Hoarseness, Nausea, Vomiting,
                  Dysphagia, Odynophagia, Weight loss

               2. Ongoing heartburn symptom with or without erosion ≥ grade A according to LA
                  Classification

          4. Ongoing heartburn symptoms ≥ 2 days during 1week right before administering first
             dose of IP

          5. Decided to participate and signed on an informed consent form willingly

        Exclusion Criteria:

          1. Existence of upper gastrointestinal bleeding or active gastroduodenal ulcer at
             screening

          2. History of operation in esophagus, stomach or duodenum

          3. The following medical history

               1. Primary esophageal motility disease, Achalasia, Scleroderma, Esophageal/pyloric
                  stricture, Primary esophageal spasm

               2. Barrett's esophagus ≥ 3 cm

               3. Zollinger-Ellison syndrome

               4. Infectious or inflammatory bowel disease, Severe malabsorption

          4. Severe chronic heart failure, cardiovascular disease, renal failure, COPD, asthma,
             liver cirrhosis

          5. History of cancer within 5 years, except completely recovered skin cancer

          6. ALT or AST ≥ Upper limit of normal range X 3

          7. Need antibiotics due to severe infection

          8. Severe medical disease that needs these prohibited medication

               -  Anticoagulant(Heparin, Warfarin, etc.), High dose of aspirin(&gt;325mg/d),
                  Digitalis(Digoxin, etc.), Diuretics, Atazanavir, NSAIDs or Steroids

          9. Use PPIs or H2RA medicine within 1 week before administering first dose of IP, or
             need other PPIs or H2RA medicine during trial period

         10. Allergy or hypersensitivity to IP or similar chemical structure(Benzimidazol
             derivatives, etc.)

         11. Pregnant or breast-feeding women

         12. Conversation impairment because of alcohol, drug addiction or mental illness, etc.

         13. Administration of other IP within 28 days

         14. Inability to record heartburn diary card

         15. In investigator's judgement
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jongsun Rew, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonnam National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sungbum Cho, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonnam National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jongsun Rew, Ph.D</last_name>
    <phone>+82-62-220-6202</phone>
    <email>jsrew@jnu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sungbum Cho, Ph.D</last_name>
    <phone>+82-61-379-7604</phone>
    <email>portalvein@naver.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <state>Donggu, Jebongro</state>
        <zip>501-757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jongsun Rew, Ph.D</last_name>
      <phone>+82-62-220-6202</phone>
      <email>jsrew@jnu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Jongsun Rew, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Gwangju</city>
        <state>Hwasun-eup,Hwasun-gun</state>
        <zip>519-763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sungbum Cho, Ph.D</last_name>
      <phone>+82-61-379-7604</phone>
      <email>portalvein@naver.com</email>
    </contact>
    <investigator>
      <last_name>Sungbum Cho, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>January 27, 2014</lastchanged_date>
  <firstreceived_date>May 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Refractory Reflux Esophagitis</keyword>
  <keyword>GERD</keyword>
  <keyword>Phase 4</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Esophagitis, Peptic</mesh_term>
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rabeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
